



Clinical Trial Details (PDF Generation Date :- Fri, 23 Oct 2020 21:32:40 GMT)

CTRI Number	CTRI/2020/04/024749 [Registered on: 21/04/2020] - Trial Registered Prospectively	
Last Modified On	22/07/2020	
Post Graduate Thesis	No	
Type of Trial	Interventional	
Type of Study	Vaccine	
Study Design	Randomized, Parallel Group, Placebo Controlled Trial	
Public Title of Study	Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects	
Scientific Title of Study	A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects	
Secondary IDs if Any	Secondary ID	Identifier
	SII-rBCG/COVID-19/IN-01, version 3.0, dated 11.04.2020	Protocol Number
Details of Principal Investigator or overall Trial Coordinator (multi-center study)	Details of Principal Investigator	
	Name	Dr Hitt Sharma
	Designation	Additional Medical Director
	Affiliation	Serum Institute Of India Pvt. Ltd.
	Address	Serum Institute Of India Pvt. Ltd. 212/2, Hadapsar, Pune India Pune Pune MAHARASHTRA 411028 India
	Phone	02026602451
	Fax	
	Email	drhjs@seruminstitute.com
Details Contact Person (Scientific Query)	Details Contact Person (Scientific Query)	
	Name	Dr Hitt Sharma
	Designation	Additional Medical Director
	Affiliation	Serum Institute Of India Pvt. Ltd.
	Address	Serum Institute Of India Pvt. Ltd. 212/2, Hadapsar, Pune India Pune Pune MAHARASHTRA 411028 India
	Phone	02026602451
	Fax	
	Email	drhjs@seruminstitute.com
Details Contact Person (Public Query)	Details Contact Person (Public Query)	
	Name	Dr Umesh Shaligram
	Designation	Director Research and Development
	Affiliation	Serum Institute Of India Pvt. Ltd.
	Address	Serum Institute Of India Pvt. Ltd. 212/2, Hadapsar, Pune India Pune Pune MAHARASHTRA 411028 India
	Phone	02026602435



	Fax			
	Email	umesh.shaligram@seruminstitute.com		
Source of Monetary or Material Support	Source of Monetary or Material Support			
	> Serum Institute of India Pvt. Ltd.			
Primary Sponsor	Primary Sponsor Details			
	Name	Serum Institute of India Pvt Ltd		
	Address	212/2 Hadapsar Pune 411028		
	Type of Sponsor	Pharmaceutical industry-Indian		
Details of Secondary Sponsor	Name	Address		
	NIL	NIL		
Countries of Recruitment	List of Countries			
	India			
Sites of Study	Name of Principal Investigator	Name of Site	Site Address	Phone/Fax/Email
	Dr Sabah Siddiqui	All India Institute of Medical Sciences	Talibandh G.E.Road, Raipur-492099. Raipur CHHATTISGARH	8518881911 dr.sabah@aiimsraipur.edu.in
	Dr Jayasree Krishnan	Apollo Speciality Hospital	Plot No 64, Vanagaram-Ambattur Rd, Ayanambakkam, Kil Ayanambakkam, Chennai-600095, Tamil Nadu Chennai TAMIL NADU	9840411858 jayasree.krishnan@yahoo.co.in
	Dr Muralidhar Tambe	B. J. Medical College	Jai Prakash Narayan Road, Near Pune Railway Station, Pune - 411001, Maharashtra, India Pune MAHARASHTRA	9423007898 deanbjmcpune@gmail.com
	Dr Bhaskar Deshmukh	Baramati Hospital	New Indapur Ring Road, behind K Moropant Sabhagruha, Near Central Building, Baramati-413102, Maharashtra. Pune MAHARASHTRA	02112-220940 bhaskar.jedhe@gmail.com
	Dr Suninder Singh Arora	Batra Hospital and Medical Research Centre	1 Tughlakabad Institutional Area, Mehrauli Badarpur Road New Delhi-110062 South DELHI	9810113414 drssarora@gmail.com
	Dr Sanjay Lalwani	Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital	Bharati Vidyapeeth (Deemed to be University) Medical College & Hospital, Department of Pediatrics, Pune-Satara Road, Katraj Dhankawa	9822051716 sanjaylalwani2007@rediffmail.com



		di,Pune-411043 Pune MAHARASHTRA	
Dr Nita Shanbhag	Dr D Y Patil Hospital	Dr D Y Patil Vidyanagar, Sector 5, Nerul, Navi Mumbai, Maharashtra Mumbai MAHARASHTRA	9322402424 nita@eyesurgeon.in
Dr Kirti Sabnis	Fortis Hospitals Limited	101, Mulund Goregaon Link Road, Bhandup West, Mumbai, Maharashtra - 400078 India Mumbai MAHARASHTRA	9626553112 drkirtisangeet@gmail.com
Dr Avinash Gawande	Government Medical College and Hospital	Medical College Square Road, Nagpur-440003, Maharashtra Nagpur MAHARASHTRA	9822224020 dravinashgawande@gmail.com
Dr Preeti Meshram	Grant Medical College & Sir JJ Hospital	J J Marg, Nagpada, Mumbai Central, Mumbai, Maharashtra 400008 Mumbai MAHARASHTRA	923198298 drpritimeshram@gmail.com
Dr Kapil Zirpe	Grant Medical Foundation Ruby Hall Clinic	40, Sassoon Road, Pune – 411001, Maharashtra, India Pune MAHARASHTRA	9822844212 kapilzirpe@gmail.com
Dr Ashwin Porwal	Healing Hands Clinic	4th Floor, Millennium Star Extension, Adjacent to Ruby Hall Entrance Gate, Dhole Patil Road, Pune-411001, Maharashtra. Pune MAHARASHTRA	9822347770 drashwinporwal@gmail.com
Dr Raman Sardana	Indraprastha Apollo Hospitals,	Mathura Rd, Sarita Vihar, New Delhi, Delhi 110076 South DELHI	9811057511 ramansardana@hotmail.com
Dr Piyush Chaudhari	Jehangir Hospital	Jehangir Hospital,Sassoon Road, Pune – 411001, Maharashtra. Pune MAHARASHTRA	9341313022 drpiyushchaudhari85@gmail.com
Dr Pradeep Dcosta	KEM Hospital Research Centre	KEM Hospital Research Centre Sardar Moodliar Road, Rasta Peth, Pune 411011 Pune MAHARASHTRA	02066037342 pradeepdcosta@yahoo.co.in



Dr Himanshu Dandu	King Georges Medical University	Chowk Lucknow 226003, Uttar Pradesh Lucknow UTTAR PRADESH	9839266822 dr.himanshu.reddy@gmail.com
Dr Sujata Patil	Krishna Institute of Medical Sciences	Agashivnagar, Malkapur, Karad-415539 Satara MAHARASHTRA	9518723884 kimsmedcollege@gmail.com
Dr Deepak Tayade	Mahatma Gandhi Mission hospital MGM Medical College & Hospital	N-6, CIDCO, Aurangabad – 43100 Aurangabad MAHARASHTRA	8788416747 drtayadeps@gmail.com
Dr Arun Puri	Max Super Speciality Hospital	108-A, IP Extension , Patparganj, New Delhi -110092 East DELHI	9811074379 arun.puri@maxhealthcare.com
Dr R S Mishra	Max Super Speciality Hospital	Saket East Block, A unit of Devki Devi Foundation, 2, Press Enclave Road, Saket, New Delhi-110017 South DELHI	9810193145 rs.mishra@maxhealthcare.com
Dr Vikas Laxman	Mysore Medical College and Research Institute	Irwin Road, Mysuru-570001, Karnataka Mysore KARNATAKA	08214244081 vikilaxman@gmail.com
Dr Shanta Dutta	National Institute of Cholera and Enteric Diseases	P- C.I.T. Scheme XM, 33, CIT Rd, Subhas Saroj Park, Phool Bagan, Belehata, Kolkata, West Bengal 700010 Kolkata WEST BENGAL	9830152971 drshantadutta@gmail.com
Dr Aparna Kodre	Noble Hospitals Pvt. Ltd	153, Magarpatta City Road, Hadapsar, Pune - 411013, Maharashtra, India Pune MAHARASHTRA	9850136436 draparnankodre@gmail.com
Dr Ashish Bhalla	Postgraduate Institute of Medical Education and Research	Sector 12, Chandigarh-160012 Chandigarh CHANDIGARH	9417023973 bhalla.chd@gmail.com
Dr Vijay Kumar Patil	Prakash Institute of Medical Sciences & Research	Urun Islampur, Islampur-Sangli Road, Islampur, Tal-Walwa, Sangli-415409. Maharashtra. Sangli MAHARASHTRA	02342662300 prakashmc.research@gmail.com
Dr Savita Verma	PT. B D Sharma Post Graduate Institute of Medical Sciences	PT. B D Sharma Post Graduate Institute of Medical Sciences,	9812283746 verma.savi@gmail.com



		University of Health Sciences, Rohtak-124001 Rohtak HARYANA	
Dr Sunita Ramanand	Rajarshee Chhatrapati Shahu Maharaj Government Medical College and Hospital	Dasara Chowk, Town hall, Kolhapur-416002 Kolhapur MAHARASHTRA	9158592177 rcsmgmc.research@gmail.com
Dr Prasita Kshirsagar	Rajiv Gandhi Medical College & Chhatrapati Shivaji Maharashtra Hospital	Kalwa West, Budhaji Nagar, Kalwa, Thane, Maharashtra 400605 Thane MAHARASHTRA	9867936579 prasitapk@yahoo.co.in
Dr Govind Kulkarni	Shayadri Super Speciality Hospital	Survey No. 185A, Shastri Nagar, Near MSEB Office, Yerawada, Nagar Road, pune-41 1006, Maharashtra Pune MAHARASHTRA	9822081168 drgdk2001@yahoo.com
Dr Atul Gogia	Sir Ganga Ram Hospital	Old Rajinder Nagar, Rajinder Nagar, New Delhi, Delhi 110060 New Delhi DELHI	9891003450 atulgogs@gmail.com
Dr Rupal Dosi	Sir Sayajirao General Hospital	SSG hospital, Jail Rd, Indira Avenue, Vadodara, Gujarat 390001 Vadodara GUJARAT	9824083734 rupal265@yahoo.com
Dr Ramakrishnan	Sri Ramachandra Institute of Higher Education and Research	No 1, Ramachandran Nagar, Porur, Chennai -600116 Chennai TAMIL NADU	9940046670 tramakrishnan@hotmail.com
Dr Poorna Prasad	Sri Venkateshwara Hospitals	No-27, 29th Main Road, Rashtra Kuvempu Nagara, BTM 2nd Stage, BTM Layout, Bengaluru-560076, Karnataka Bangalore KARNATAKA	08025630006 spoonaprasad123@gmail.com
Dr Nellaippa Ganesan	SRM College Chennai	SRM Nagar, Kattankulathur, Chengalpattu, Tamil Nadu - 603203 Kancheepuram TAMIL NADU	9361860009 nells220152@gmail.com
Dr Abhay Vispute	SRV Hospital	Dr Mandakini Parihar Marg opposite Lokmanya Tilak Terminus, Tilak Nagar, Chembur, Mumbai, Maharashtra 400089	02250120000 surgician@gmail.com



		Mumbai MAHARASHTRA	
Dr Urvi Shukla	Symbiosis University Hospital and Research Centre	Symbiosis International University, Gram Lavale, Tal. Mulshi, Pune - 412115 Pune MAHARASHTRA	9922994977 shuklaurvi@yahoo.com
Dr Renuka Munshi	TNMC & NAIR HSOPITAL	55,Dr Anandrao Nair Marg, Mumbai Central, Mumbai, Maharashtra, 400008 Mumbai MAHARASHTRA	9811131719 raj.rkmjs@gmail.com
Dr Abhishek Karmalkar	Vedant Multispeciality Hospital	Sambhaji Nagar, Chinchwad, Pimpri-Chi nchwad-411019, Maharashtra. Pune MAHARASHTRA	9850337271 dr.karmalkar@gmail.co m
Dr Pravin Soni	Yashwantrao Chavan Memorial Hospital	YCM Hospital Road, Sant Tukaram Nagar, Pimpri Colony, Pune - 411018, Maharashtra, India Pune MAHARASHTRA	9822057511 drpravinsoni18@gmail. com

**Details of Ethics
Committee**

Name of Committee	Approval Status	Date of Approval	Is Independent Ethics Committee?
Aditya Jyot Eye Hospital Ethics Committee, Mumbai	Approved	10/06/2020	No
Ethics Committee For Research On Human Subjects, MGM Aurangabad	Approved	07/05/2020	No
Ethics Committee of Pulse Multispeciality Hospital, Pune	Approved	29/04/2020	No
Ethics Committee, Jehangir Clinical Development Centre Pvt Ltd	Approved	27/04/2020	No
Ethics Committee, PGI Chandigarh	Approved	27/04/2020	No
Ethics Committee, Rao Nursing Home, Pune	Approved	28/04/2020	No
IEC, PCMCs, PGI, Yashwantrao Chavan Memorial Hospital	Approved	12/06/2020	No
Independent Ethics Committee of Symbiosis International University	Approved	12/05/2020	No
Institutional Clinical Ethics Committee , RGMC & CSMH, Thane	Approved	13/05/2020	No



Institutional Ethics Committee King Georges Medical University	Approved	06/05/2020	No
Institutional Ethics Committee, RCSMGMCIEC II, Kolhapur	Approved	29/04/2020	No
Institutional Ethics Committee National Institute of Cholera and Enteric Diseases	Approved	18/05/2020	No
Institutional Ethics Committee - Clinical Studies, Apollo Hospital, Chennai	Approved	29/05/2020	No
Institutional Ethics Committee Bharati Vidyapeeth Deemed University	Approved	29/04/2020	No
Institutional Ethics Committee for Human Research, Baroda Medical College, Vadodara	Approved	20/05/2020	No
Institutional Ethics Committee Max Super Speciality Hospital, Patparganj	Approved	05/05/2020	No
Institutional Ethics Committee Max Super Speciality Hospital, Saket	Approved	22/04/2020	No
Institutional Ethics Committee Mysore Medical College and Research Institute and Associated Hospitals	Approved	22/04/2020	No
Institutional Ethics Committee TNMC Nair Hospital	Approved	12/05/2020	No
Institutional Ethics Committee, AIIMS, Raipur	Approved	11/05/2020	No
Institutional Ethics Committee, B.J.G. Medical College and Sassoon General Hospitals, Pune	Approved	06/06/2020	No
Institutional Ethics Committee, D Y Patil Medical College, Navi Mumbai	Approved	01/06/2020	No
Institutional Ethics Committee, Fortis Hospital, Mumbai	Approved	09/06/2020	No
Institutional Ethics Committee,	Approved	04/05/2020	No



Government Medical College, Nagpur			
Institutional Ethics Committee, Grant Medical College, Mumbai	Approved	12/05/2020	No
Institutional Ethics Committee, Indraprastha Apollo Hospitals, New Delhi	Approved	11/05/2020	No
Institutional Ethics Committee, Krishna Institute of Medical Sciences, Karad	Approved	04/05/2020	No
Institutional Ethics Committee, Poona Medical Research Foundation, Pune	Approved	12/05/2020	No
Institutional Ethics Committee, PT. B D Sharma Post Graduate Institute of Medical Sciences, Rohtak	Approved	23/04/2020	No
Institutional Ethics Committee, SRM College Chennai	Approved	16/06/2020	No
Institutional Ethics Committee, SRMC Chennai	Approved	11/05/2020	No
KEM Hospital Research Centre Ethics Committee, Pune	Approved	20/04/2020	No
Nikop Institutional Ethics Committe	Approved	30/04/2020	No
Noble Hospital Institutional Ethics Committee	Approved	07/05/2020	No
Prakash Medical College, Institutional Ethics Committee	Approved	21/04/2020	No
Sahyadri Hospitals Ltd Ethics Committee	Approved	04/06/2020	No
Scientific Research and Ethics Review Committee, Batra Hospital and Medical Research Center, New Delhi	Approved	11/05/2020	No
Sir Ganga Ram Hospital Ethics Committee	Approved	13/06/2020	No
Sri Venkateshwara Hospitals Ethics Committee	Approved	23/04/2020	No

Regulatory Clearance Status from DCGI

Status	Date
Approved/Obtained	12/04/2020



Health Condition / Problems Studied	Health Type		Condition
	Patients		Coronavirus as the cause of diseases classified elsewhere
	Patients		Encounter for immunization
Intervention / Comparator Agent	Type	Name	Details
	Intervention	recombinant BCG vaccine, VPM1002	Dose : 0.1 ml, single dose of the reconstituted vaccine to be administered as an intradermal injection
	Comparator Agent	Placebo, 0.9% sodium chloride	Dose : 0.1 ml, single dose to be administered as an intradermal injection
Inclusion Criteria	Inclusion Criteria		
	Age From	18.00 Year(s)	
	Age To	99.00 Year(s)	
	Gender	Both	
	Details	1. Male or Female subjects ? 18 years of age at high-risk of SARS-CoV-2/COVID-19 infection 2. Test negative for SARS-CoV-2 infection (RT-PCR test) at screening 3. Capable of giving informed consent	
Exclusion Criteria	Exclusion Criteria		
	Details	1. Previous history of Tuberculosis or known active Mycobacterium tuberculosis infection 2. Received BCG vaccine within one year prior to screening 3. Fever (greater than or equal to 38 °C/100.4°F) or any other respiratory symptoms/illnesses within the past 14 days 4. Pregnant or lactating women 5. Women of child-bearing potential not agreeing to use adequate contraception 6. Current active viral or bacterial infection 7. Expected vaccination during the study period, independently of the type of vaccination 8. Severely immunocompromised subjects. 9. Active solid or non-solid malignancy or lymphoma within the prior two years 10. Individuals known to be hypersensitive to any component of the vaccine 11. Eczema or other significant skin lesion or infection at the site/s of injection. 12. Any other medical condition which in the opinion of the investigator may affect the subject's safety or study participation and conduct	
Method of Generating Random Sequence	Computer generated randomization		
Method of Concealment	Centralized		
Blinding/Masking	Participant, Investigator, Outcome Assessor and Data-entry Operator Blinded		
Primary Outcome	Outcome	Timepoints	
	1.Number of subjects with laboratory confirmed COVID-19 infection among HCWs 2.Number of subjects with laboratory confirmed COVID-19 infection among other high-risk subjects	up to 6 months (180 days) following vaccine administration	



	3.Number of laboratory confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by Investigator among HCWs 4.Number of laboratory confirmed COVID-19 infection with severe, critical or life-threatening disease as assessed by Investigator among other high-risk subjects					
Secondary Outcome	<table border="1"> <thead> <tr> <th>Outcome</th> <th>Timepoints</th> </tr> </thead> <tbody> <tr> <td>1.Duration of COVID-19 symptoms in HCWs 2.Duration of COVID-19 symptoms in other high-risk subjects 3.Severe Disease Outcomes in HCWs 4.Severe Disease Outcomes in other high-risk subjects 5.Severe Disease Outcomes among in elderly subjects (greater than or equal to 60 years) 6.Severe Disease Outcomes among subjects with Co-morbidities 7.Incidence of Adverse Events and Serious Adverse Events</td> <td>up to 6 months (180 days) following vaccine administration</td> </tr> </tbody> </table>	Outcome	Timepoints	1.Duration of COVID-19 symptoms in HCWs 2.Duration of COVID-19 symptoms in other high-risk subjects 3.Severe Disease Outcomes in HCWs 4.Severe Disease Outcomes in other high-risk subjects 5.Severe Disease Outcomes among in elderly subjects (greater than or equal to 60 years) 6.Severe Disease Outcomes among subjects with Co-morbidities 7.Incidence of Adverse Events and Serious Adverse Events	up to 6 months (180 days) following vaccine administration	
Outcome	Timepoints					
1.Duration of COVID-19 symptoms in HCWs 2.Duration of COVID-19 symptoms in other high-risk subjects 3.Severe Disease Outcomes in HCWs 4.Severe Disease Outcomes in other high-risk subjects 5.Severe Disease Outcomes among in elderly subjects (greater than or equal to 60 years) 6.Severe Disease Outcomes among subjects with Co-morbidities 7.Incidence of Adverse Events and Serious Adverse Events	up to 6 months (180 days) following vaccine administration					
Target Sample Size	Total Sample Size=5946 Sample Size from India=5946 Final Enrollment numbers achieved (Total)=Applicable only for Completed/Terminated trials Final Enrollment numbers achieved (India)=Applicable only for Completed/Terminated trials					
Phase of Trial	Phase 3					
Date of First Enrollment (India)	21/04/2020					
Date of First Enrollment (Global)	No Date Specified					
Estimated Duration of Trial	Years=1 Months=0 Days=0					
Recruitment Status of Trial (Global)	Not Applicable					
Recruitment Status of Trial (India)	Closed to Recruitment of Participants					
Publication Details						
Brief Summary	<p>This is a placebo controlled, multicentric, randomized, double blind, adaptive study to evaluate the reduction in infection incidence and severity of SARS-CoV-2/ COVID-19 infection among high-risk subjects by enhanced trained immune response through VPM1002 vaccine. Subjects who provide informed consent will be assessed for eligibility criteria. The subjects who fulfill all the eligibility criteria will be randomized in a 2:1 ratio to receive a single dose (0.1 ml) of either VPM1002 or placebo, administered as an intradermal injection. The duration of follow-up will be based on the results of interim analysis however the maximum follow-up period will be up to 180 days.</p>					